| 000 | 01252 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250515194706.0 | ||
| 264 | 0 | _c20100224 | |
| 008 | 201002s 0 0 eng d | ||
| 022 | _a1875-533X | ||
| 024 | 7 |
_a10.2174/092986709789909585 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDi Pauli, F | |
| 245 | 0 | 0 |
_aMonoclonal antibodies in the treatment of multiple sclerosis. _h[electronic resource] |
| 260 |
_bCurrent medicinal chemistry _c2009 |
||
| 300 |
_a4858-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntibodies, Neoplasm _xtherapeutic use |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aDaclizumab |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 | _aNatalizumab |
| 650 | 0 | 4 | _aRituximab |
| 700 | 1 | _aBerger, T | |
| 700 | 1 | _aReindl, M | |
| 773 | 0 |
_tCurrent medicinal chemistry _gvol. 16 _gno. 36 _gp. 4858-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/092986709789909585 _zAvailable from publisher's website |
| 999 |
_c19314671 _d19314671 |
||